Healthcare, Pharma & Life Sciences

Beverly Hills – November 06, 2026 -- Beverly Hills Body Academy (BHBA) has formed as the world's first body contouring academy permanently based in Beverly Hills, with a three-chair leadership team and membership restricted to board-certified and board-eligible plastic surgeons.

Three chairs lead the academy from a Wilshire Boulevard office

Dr. Alfredo Hoyos, pioneer of HD Liposuction, and Dr. Ashkan Ghavami, creator of the S-Curve, serve as Co-Chairmen. Dr. Kiya Movassaghi, past president of The Aesthetic Society, is Scientific Chair. The academy's office is at 9465 Wilshire Boulevard, Suite 300, in the Golden Triangle of Beverly Hills.

The chairs are joined by the BHBA Academy Council: Dr. Adam Rubinstein, Dr. Ali Tehrani, Dr. Al Aly, Dr. Jerry Chidester and Dr. Alexandre Sanfurgo. The Body Contouring Academy LLC operates the academy, and Ewan Mohammed is Founder and CEO.

Bad Neustadt an der Saale – November 06, 2026 -- RHÖN-KLINIKUM Campus Bad Neustadt has appointed Dr. Stefan Reisch (MHBA) as chief physician of its Department of Anesthesiology and Intensive Care Medicine, effective November 1, 2026. Reisch has worked at the site since 2009 and filled the role on an interim basis before the permanent appointment.

Reisch led the department on an interim basis in 2024 and again from July 1, 2026

Reisch served as senior attending physician and, most recently, as permanent deputy to the chief physician. He took over interim leadership under the department's collegial system in 2024 and resumed it on July 1, 2026.

Juliane Domke, managing director of the campus, said filling the post internally gives the clinic a leader who already knows the team and structures.

LOS ANGELES – November 06, 2026 -- LaserAway has opened its 241st location in Paramus, New Jersey, extending a 20-year expansion the company says included no clinic closures.

LaserAway runs 241 company-owned clinics in 36 states

Dr. Roy Winston and brothers Scott, Brock and Todd Heckmann founded the Los Angeles-based company in 2006 with a single clinic in West Hollywood. Every location is privately owned and operated, with no franchises. The Paramus opening coincides with the company's 20th anniversary this year.

Scott Heckmann, co-founder and CEO, said the company set out to make aesthetic treatments accessible to everyone, not only a privileged few.

Wooster, Ohio – November 06, 2026 -- PRC-Saltillo, an augmentative and alternative communication (AAC) technology maker founded in 1966, has partnered with the Team Gleason Foundation to expand awareness, education and access to assistive communication technology for people with ALS and their families.

Partnership targets shifting communication needs across the ALS journey

The companies say communication needs change as ALS progresses. Navigating technologies, resources and support can overwhelm patients, care partners and clinicians alike. The partnership will deliver educational opportunities, share expertise and raise awareness of available communication solutions.

Ipswich – November 06, 2026 -- New England Biolabs (NEB) will present an integrated cfDNA and cfRNA workflow, an enzymatic DNA methylation method and a new high-fidelity PCR master mix at the Association for Molecular Pathology (AMP) Annual Meeting & Expo, held November 10-15, 2026, at the Seattle Convention Center.

NEB workshop combines Monarch purification with NEBNext library prep for multiomic profiling

The corporate workshop, "One Sample, Many Insights: Multiomic Profiling in cfDNA and cfRNA Samples," runs Wednesday, November 11, at 10:00 AM in Tahoma 3, Level 3. It pairs Monarch Nucleic Acid Purification with NEBNext NGS Library Preparation. The workflow covers extraction through sequencing, and NEB says it is designed to recover mutation, methylation and gene-expression signals from limited samples.

Berlin – November 06, 2026 -- Participants at the 34th Plattform Gesundheit of IKK e.V. agreed that Germany's primary care reform must proceed step by step and without disruptive breaks, with quality taking priority over speed. Representatives from health policy, the medical profession and self-governance, plus about 100 guests attending on site and online, debated how a primary care system can steer patients to the right level of care without becoming an additional access barrier.

SAN FRANCISCO – November 06, 2026 -- AusperBio's investigational antisense oligonucleotide AHB-137 maintained functional cure in 16 of 17 evaluable nucleos(t)ide analogue (NA)-treated chronic hepatitis B participants 12 months after they stopped all HBV treatment, according to long-term follow-up data from Study AB-10-8004. No participant required NA re-initiation during follow-up.

Nine of nine evaluable NA-treated participants stay cured at 15 months

In the NA-treated cohort, functional cure held in 9 of 9 evaluable participants at 15 months after NA discontinuation. The cohort enrolled 34 participants (21 complete responders, 13 partial responders) from the Phase 2 studies AB-10-8002 and AB-10-8003.

Durham – November 06, 2026 -- Brii Biosciences (2137.HK) reported that 41.9% of participants (62/148) in its Phase 2b ENRICH study achieved hepatitis B surface antigen (HBsAg) loss at end of treatment (EOT), with 32.4% (48/148) sustaining it 24 weeks later. The data were presented in three late-breaking sessions at the AASLD Liver Meeting in Denver, running November 5 to 9, 2026.

ENRICH reproduces the BRII-179 priming effect seen in ENSURE Cohort 4

ENRICH prospectively tested a strategy first identified in Cohort 4 of the ENSURE study, where BRII-179-experienced participants, particularly those developing anti-HBs responses, showed higher functional cure rates. Participants received BRII-179 every 3 or 2 weeks for 12 weeks before elebsiran and pegylated interferon alpha (PEG-IFNα). Results across both dose regimens matched the ENSURE observations.

BELLEVUE – November 06, 2026 -- Harrison Street Asset Management, a firm with more than $110 billion in assets under management, has formed a joint venture with Aegis Living to invest in and develop assisted living and memory care communities, starting with a three-property portfolio.

Initial portfolio covers three Aegis communities in Washington and California

The first investment spans Aegis Gardens in Newcastle, WA; Aegis Living Moraga in Moraga, CA; and Aegis Living Madison in Seattle. The partners plan to add acquisitions and development projects. Financial terms were not included in the announcement.

Aegis Living will continue to manage all three communities. Care teams, community leaders and care plans stay in place. Aegis, founded in 1997 and based in Bellevue, operates 37 communities across Washington, California and Nevada.

Addison, Texas – November 06, 2026 -- FX Shoulder Solutions has received FDA 510(k) clearance for Easytech Reversed, which the company describes as the first and only stemless reverse shoulder arthroplasty system cleared in the United States. The clearance follows nearly eight years of US clinical investigation.

Seven-site IDE study enrolled 90 patients

FX started the US Investigational Device Exemption (IDE) study in 2018. The multicenter investigation ran across seven sites and covered 90 patients. Follow-up was completed in 2023 and supports the regulatory submission, according to the company. FX also cites more than a decade of international clinical experience with its Easytech technology.